Lipophilic Efficiency as an Important Metric in Drug Design

Journal of Medicinal Chemistry

Volumn 61, Issue 15, 2018, Pages 6401-6420

  Johnson, Ted W ^a   Gallego, Rebecca A ^a   Edwards, Martin P ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND;

ARTICLE; CRYSTAL STRUCTURE; CYCLIZATION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; LIGAND BINDING; LIPOPHILIC EFFICIENCY; LIPOPHILICITY; MEDICINAL CHEMISTRY; PROCESS OPTIMIZATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; ANIMAL; CHEMICAL PHENOMENA; HUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYCLIZATION; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85048686448     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.8b00077     Document Type: Article

References (85)

1. Wenlock, M. C.; Potter, T.; Barton, P.; Austin, R. P. A method for measuring the lipophilicity of compounds in mixtures of 10. J. Biomol. Screening 2011, 16 (3), 348-355, 10.1177/1087057110396372
2. Liu, X.; Testa, B.; Fahr, A. Lipophilicity and its relationship with passive drug permeation. Pharm. Res. 2011, 28 (5), 962-977, 10.1007/s11095-010-0303-7
3. Braibanti, A.; Fisicaro, E.; Compari, C. Solubility of oxygen and inert substances in water. Polyhedron 2000, 19 (24-25), 2457-2461, 10.1016/S0277-5387(00)00545-3
4. Meyer, H. Zur theorie der alkoholnarkose. Naunyn-Schmiedeberg's Arch. Pharmacol. 1899, 42 (2-4), 109-118, 10.1007/BF01834479
5. Meyer, H. Zur theorie der alkoholnarkose. Naunyn-Schmiedeberg's Arch. Pharmacol. 1901, 46 (5-6), 338-346, 10.1007/BF01978064
6. Richet, M. C. Sur le rapport Entre la toxicité et les propriétés des corps. C. R. Seances Soc. Biol. 1893, 9, 775-776
7. Waring, M. J. Lipophilicity in drug discovery. Expert Opin. Drug Discovery 2010, 5 (3), 235-248, 10.1517/17460441003605098
8. Hansch, C. Quantitative approach to biochemical structure-activity relationships. Acc. Chem. Res. 1969, 2 (8), 232-239, 10.1021/ar50020a002
9. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23 (1-3), 3-25, 10.1016/S0169-409X(96)00423-1
10. Huang, Q.; Johnson, T. W.; Bailey, S.; Brooun, A.; Bunker, K. D.; Burke, B. J.; Collins, M. R.; Cook, A. S.; Cui, J. J.; Dack, K. N.; Deal, J. G.; Deng, Y.-L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.; Hoffman, R. L.; Johnson, P. S.; Kania, R. S.; Lam, H.; Lam, J. L.; Le, P. T.; Li, Q.; Lingardo, L.; Liu, W.; Lu, M. W.; McTigue, M.; Palmer, C. L.; Richardson, P. F.; Sach, N. W.; Shen, H.; Smeal, T.; Smith, G. L.; Stewart, A. E.; Timofeevski, S.; Tsaparikos, K.; Wang, H.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards, M. P. Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J. Med. Chem. 2014, 57 (4), 1170-1187, 10.1021/jm401805h
11. Freire, E. Do enthalpy and entropy distinguish first in class from best in class?. Drug Discovery Today 2008, 13 (19-20), 869-874, 10.1016/j.drudis.2008.07.005
12. Ruben, A. J.; Kiso, Y.; Freire, E. Overcoming roadblocks in lead optimization: A thermodynamic perspective. Chem. Biol. Drug Des. 2006, 67 (1), 2-4, 10.1111/j.1747-0285.2005.00314.x
13. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44 (1), 235-249, 10.1016/S1056-8719(00)00107-6
14. Meanwell, N. A. Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space. Chem. Res. Toxicol. 2016, 29 (4), 564-616, 10.1021/acs.chemrestox.6b00043
15. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the golden triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 2009, 19 (19), 5560-5564, 10.1016/j.bmcl.2009.08.045
16. Leeson, P. D.; Davis, A. M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47 (25), 6338-6348, 10.1021/jm049717d
17. Birkett, D. J. Pharmacokinetics made easy 9: Non-linear pharmacokinetics. Australian Prescriber 1994, 17 (2), 36-38, 10.18773/austprescr.1994.046
18. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods; Elsevier, 2008; pp 386-398.
19. Smith, D. A., Allerton, C., Kalgutkar, A. S., van de Waterbeemd, H., Walker, D. K., Eds. Pharmacokinetics and Metabolism in Drug Design, 3 rd ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2012.
20. Kaplowitz, N. Avoiding idiosyncratic DILI: two is better than one. Hepatology 2013, 58 (1), 15-17, 10.1002/hep.26295
21. Seguin, B.; Uetrecht, J. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin Allergy Clin Immunol 2003, 3 (4), 235-242, 10.1097/00130832-200308000-00001
22. Touloukian, J.; Kaplowitz, N. Halothane-induced hepatic disease. Semin. Liver Dis. 1981, 1 (2), 134-142, 10.1055/s-2008-1040726
23. Ulrich, R. G. Idiosyncratic toxicity: a convergence of risk factors. Annu. Rev. Med. 2007, 58, 17-34, 10.1146/annurev.med.58.072905.160823
24. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discovery 2011, 10 (3), 197-208, 10.1038/nrd3367
25. Borchard, U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin. Physiol. Biochem. 1990, 8 (Suppl. 2), 28-34
26. Ritchie, T. J.; Luscombe, C. N.; Macdonald, S. J. F. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?. J. Chem. Inf. Model. 2009, 49 (4), 1025-1032, 10.1021/ci800429e
27. Yalkowsky, S. H.; Valvani, S. C. Solubility and partitioning I: solubility of nonelectrolytes in water. J. Pharm. Sci. 1980, 69 (8), 912-922, 10.1002/jps.2600690814
28. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett. 2009, 19 (10), 2844-2851, 10.1016/j.bmcl.2009.03.109
29. Camenisch, G.; Alsenz, J.; van de Waterbeemd, H.; Folkers, G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 1998, 6 (4), 313-319, 10.1016/S0928-0987(97)10019-7
30. Shugarts, S.; Benet, L. Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 2009, 26 (9), 2039-2054, 10.1007/s11095-009-9924-0
31. Yang, N. J.; Hinner, M. J. Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol. Biol. 2015, 1266, 29-53, 10.1007/978-1-4939-2272-7-3
32. Mannhold, R.; Poda, G. I.; Ostermann, C.; Tetko, I. V. Calculation of molecular lipophilicity: state-of-the-art and comparison of logP methods on more than 96,000 compounds. J. Pharm. Sci. 2009, 98 (3), 861-893, 10.1002/jps.21494
33. Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. Future Med. Chem. 2013, 5 (2), 113-115, 10.4155/fmc.12.208
34. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6 (11), 881-890, 10.1038/nrd2445
35. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis. Bioorg. Med. Chem. Lett. 2009, 19 (15), 4406-4409, 10.1016/j.bmcl.2009.05.062
36. Guo, D.; Heitman, L. H.; Ijzerman, A. P. The added value of assessing ligand-receptor binding kinetics in drug discovery. ACS Med. Chem. Lett. 2016, 7 (9), 819-821, 10.1021/acsmedchemlett.6b00273
37. Pan, A. C.; Borhani, D. W.; Dror, R. O.; Shaw, D. E. Molecular determinants of drug-receptor binding kinetics. Drug Discovery Today 2013, 18 (13-14), 667-673, 10.1016/j.drudis.2013.02.007
38. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9 (10), 430-431, 10.1016/S1359-6446(04)03069-7
39. Keserü, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discovery 2009, 8 (3), 203-212, 10.1038/nrd2796
40. Reynolds, C. H.; Bembenek, S. D.; Tounge, B. A. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 2007, 17 (15), 4258-4261, 10.1016/j.bmcl.2007.05.038
41. Tarcsay, á.; Nyíri, K.; KeseruÌ, G. M. Impact of lipophilic efficiency on compound quality. J. Med. Chem. 2012, 55 (3), 1252-1260, 10.1021/jm201388p
42. Shultz, M. D. The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations. Bioorg. Med. Chem. Lett. 2013, 23 (21), 5992-6000, 10.1016/j.bmcl.2013.08.030
43. Stepan, A. F.; Kauffman, G. W.; Keefer, C. E.; Verhoest, P. R.; Edwards, M. Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis. J. Med. Chem. 2013, 56 (17), 6985-6990, 10.1021/jm4008642
44. Edwards, M. P.; Price, D. A. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks. Annu. Rep. Med. Chem. 2010, 45, 380-391, 10.1016/S0065-7743(10)45023-X
45. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18 (17), 4872-4875, 10.1016/j.bmcl.2008.07.071
46. Kramer, J. A.; Sagartz, J. E.; Morris, D. L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discovery 2007, 6 (8), 636-649, 10.1038/nrd2378
47. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties. MedChemComm 2011, 2 (2), 91-105, 10.1039/C0MD00157K
48. Moroy, G.; Martiny, V. Y.; Vayer, P.; Villoutreix, B. O.; Miteva, M. A. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discovery Today 2012, 17 (1-2), 44-55, 10.1016/j.drudis.2011.10.023
49. Tetko, I. V.; Bruneau, P.; Mewes, H.-W.; Rohrer, D. C.; Poda, G. I. Can we estimate the accuracy of ADME-Tox predictions?. Drug Discovery Today 2006, 11 (15-16), 700-707, 10.1016/j.drudis.2006.06.013
50. Johnson, T. W.; Richardson, P. F.; Bailey, S.; Brooun, A.; Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.; Deng, Y.-L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.; Hoffman, R. L.; Huang, Q.; Kania, R. S.; Kath, J. C.; Lam, H.; Lam, J. L.; Le, P. T.; Lingardo, L.; Liu, W.; McTigue, M.; Palmer, C. L.; Sach, N. W.; Smeal, T.; Smith, G. L.; Stewart, A. E.; Timofeevski, S.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards, M. P. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 2014, 57 (11), 4720-4744, 10.1021/jm500261q
51. Brockunier, L. L.; He, J.; Colwell, L. F.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Teffera, Y.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2004, 14 (18), 4763-4766, 10.1016/j.bmcl.2004.06.065
52. Hagmann, W. K. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 2008, 51 (15), 4359-4369, 10.1021/jm800219f
53. Kim, D.; Kowalchick, J. E.; Brockunier, L. L.; Parmee, E. R.; Eiermann, G. J.; Fisher, M. H.; He, H.; Leiting, B.; Lyons, K.; Scapin, G.; Patel, S. B.; Petrov, A.; Pryor, K. D.; Roy, R. S.; Wu, J. K.; Zhang, X.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. Discovery of potent and selective dipeptidyl peptidase IV Inhibitors derived from β-aminoamides bearing subsituted triazolopiperazines. J. Med. Chem. 2008, 51 (3), 589-602, 10.1021/jm070330v
54. Schweizer, E.; Hoffmann-Röder, A.; Schärer, K.; Olsen, J. A.; Fäh, C.; Seiler, P.; Obst-Sander, U.; Wagner, B.; Kansy, M.; Diederich, F. A Fluorine scan at the catalytic center of thrombin: C-F, C-OH, and C-OMe bioisosterism and fluorine effects on pKa and logD values. ChemMedChem 2006, 1 (6), 611-621, 10.1002/cmdc.200600015
55. Johnson, T. W.; Tanis, S. P.; Butler, S. L.; Dalvie, D.; DeLisle, D. M.; Dress, K. R.; Flahive, E. J.; Hu, Q.; Kuehler, J. E.; Kuki, A.; Liu, W.; McClellan, G. A.; Peng, Q.; Plewe, M. B.; Richardson, P. F.; Smith, G. L.; Solowiej, J.; Tran, K. T.; Wang, H.; Yu, X.; Zhang, J.; Zhu, H. Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 Integrase inhibitors. J. Med. Chem. 2011, 54 (9), 3393-3417, 10.1021/jm200208d
56. Chen, X.; Tsiang, M.; Yu, F.; Hung, M.; Jones, G. S.; Zeynalzadegan, A.; Qi, X.; Jin, H.; Kim, C. U.; Swaminathan, S.; Chen, J. M. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 2008, 380 (3), 504-519, 10.1016/j.jmb.2008.04.054
57. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P.-P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 2011, 54 (18), 6342-6363, 10.1021/jm2007613
58. Toogood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; VanderWel, S. N.; Zhou, H.; Keller, P. R.; McNamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J. Med. Chem. 2005, 48 (7), 2388-2406, 10.1021/jm049354h
59. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (18), 9997-10002, 10.1073/pnas.96.18.9997
60. Shamovsky, I.; de Graaf, C.; Alderin, L.; Bengtsson, M.; Bladh, H. k.; Börjesson, L.; Connolly, S.; Dyke, H. J.; van den Heuvel, M.; Johansson, H.; Josefsson, B.-G. r.; Kristoffersson, A.; Linnanen, T.; Lisius, A.; Männikkö, R.; Nordén, B.; Price, S.; Ripa, L.; Rognan, D.; Rosendahl, A.; Skrinjar, M.; Urbahns, K. Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites. J. Med. Chem. 2009, 52 (23), 7706-7723, 10.1021/jm900713y
61. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin. Drug Discovery 2008, 3 (12), 1427-1449, 10.1517/17460440802580106
62. Barreiro, E. J.; Kummerle, A. E.; Fraga, C. A. The methylation effect in medicinal chemistry. Chem. Rev. 2011, 111 (9), 5215-46, 10.1021/cr200060g
63. Klebl, B. M.; Muller, G. Second-generation kinase inhibitors. Expert Opin. Ther. Targets 2005, 9 (5), 975-993, 10.1517/14728222.9.5.975
64. Schönherr, H.; Cernak, T. Profound methyl effects in drug discovery and a call for new C-H methylation reactions. Angew. Chem., Int. Ed. 2013, 52 (47), 12256-12267, 10.1002/anie.201303207
65. Smith, D. A.; van de Waterbeemd, H.; Walker, D. K. Pharmacokinetics and Metabolism in Drug Design. In Methods and Principles in Medicinal Chemistry; Wiley-VCH Verlag GmbH, 2001.
66. Leung, C. S.; Leung, S. S. F.; Tirado-Rives, J.; Jorgensen, W. L. Methyl effects on protein-ligand binding. J. Med. Chem. 2012, 55 (9), 4489-4500, 10.1021/jm3003697
67. Kung, P.-P.; Rui, E.; Bergqvist, S.; Bingham, P.; Braganza, J.; Collins, M.; Cui, M.; Diehl, W.; Dinh, D.; Fan, C.; Fantin, V. R.; Gukasyan, H. J.; Hu, W.; Huang, B.; Kephart, S.; Krivacic, C.; Kumpf, R. A.; Li, G.; Maegley, K. A.; McAlpine, I.; Nguyen, L.; Ninkovic, S.; Ornelas, M.; Ryskin, M.; Scales, S.; Sutton, S.; Tatlock, J.; Verhelle, D.; Wang, F.; Wells, P.; Wythes, M.; Yamazaki, S.; Yip, B.; Yu, X.; Zehnder, L.; Zhang, W.-G.; Rollins, R. A.; Edwards, M. Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors. J. Med. Chem. 2016, 59 (18), 8306-8325, 10.1021/acs.jmedchem.6b00515
68. Howard, E. I.; Sanishvili, R.; Cachau, R. E.; Mitschler, A.; Chevrier, B.; Barth, P.; Lamour, V.; Van Zandt, M.; Sibley, E.; Bon, C.; Moras, D.; Schneider, T. R.; Joachimiak, A.; Podjarny, A. Ultrahigh resolution drug design I: Details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Proteins: Struct., Funct., Genet. 2004, 55 (4), 792-804, 10.1002/prot.20015
69. Van Zandt, M. C.; Sibley, E. O.; McCann, E. E.; Combs, K. J.; Flam, B.; Sawicki, D. R.; Sabetta, A.; Carrington, A.; Sredy, J.; Howard, E.; Mitschler, A.; Podjarny, A. D. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications. Bioorg. Med. Chem. 2004, 12 (21), 5661-5675, 10.1016/j.bmc.2004.07.062
70. Hansch, C.; Leo, A.; Hoekman, D. H. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants; American Chemical Society, 1995; p 348.
71. Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry. ChemBioChem 2004, 5 (5), 637-643, 10.1002/cbic.200301023
72. Muller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: Looking beyond intuition. Science 2007, 317 (5846), 1881-1886, 10.1126/science.1131943
73. Shah, P.; Westwell, A. D. The role of fluorine in medicinal chemistry. J. Enzyme Inhib. Med. Chem. 2007, 22 (5), 527-540, 10.1080/14756360701425014
74. Cheng, H.; Nair, S. K.; Murray, B. W.; Almaden, C.; Bailey, S.; Baxi, S.; Behenna, D.; Cho-Schultz, S.; Dalvie, D.; Dinh, D. M.; Edwards, M. P.; Feng, J. L.; Ferre, R. A.; Gajiwala, K. S.; Hemkens, M. D.; Jackson-Fisher, A.; Jalaie, M.; Johnson, T. O.; Kania, R. S.; Kephart, S.; Lafontaine, J.; Lunney, B.; Liu, K. K. C.; Liu, Z.; Matthews, J.; Nagata, A.; Niessen, S.; Ornelas, M. A.; Orr, S. T. M.; Pairish, M.; Planken, S.; Ren, S.; Richter, D.; Ryan, K.; Sach, N.; Shen, H.; Smeal, T.; Solowiej, J.; Sutton, S.; Tran, K.; Tseng, E.; Vernier, W.; Walls, M.; Wang, S.; Weinrich, S. L.; Xin, S.; Xu, H.; Yin, M.-J.; Zientek, M.; Zhou, R.; Kath, J. C. Discovery of 1-{(3R,4R)-3-[({5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants. J. Med. Chem. 2016, 59 (5), 2005-2024, 10.1021/acs.jmedchem.5b01633
75. Planken, S.; Behenna, D. C.; Nair, S. K.; Johnson, T. O.; Nagata, A.; Almaden, C.; Bailey, S.; Ballard, T. E.; Bernier, L.; Cheng, H.; Cho-Schultz, S.; Dalvie, D.; Deal, J. G.; Dinh, D. M.; Edwards, M. P.; Ferre, R. A.; Gajiwala, K. S.; Hemkens, M.; Kania, R. S.; Kath, J. C.; Matthews, J.; Murray, B. W.; Niessen, S.; Orr, S. T. M.; Pairish, M.; Sach, N. W.; Shen, H.; Shi, M.; Solowiej, J.; Tran, K.; Tseng, E.; Vicini, P.; Wang, Y.; Weinrich, S. L.; Zhou, R.; Zientek, M.; Liu, L.; Luo, Y.; Xin, S.; Zhang, C.; Lafontaine, J. Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: A high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR. J. Med. Chem. 2017, 60 (7), 3002-3019, 10.1021/acs.jmedchem.6b01894
76. Flanagan, M. E.; Blumenkopf, T. A.; Brissette, W. H.; Brown, M. F.; Casavant, J. M.; Shang-Poa, C.; Doty, J. L.; Elliott, E. A.; Fisher, M. B.; Hines, M.; Kent, C.; Kudlacz, E. M.; Lillie, B. M.; Magnuson, K. S.; McCurdy, S. P.; Munchhof, M. J.; Perry, B. D.; Sawyer, P. S.; Strelevitz, T. J.; Subramanyam, C.; Sun, J.; Whipple, D. A.; Changelian, P. S. Discovery of CP-690,550: A potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 2010, 53 (24), 8468-8484, 10.1021/jm1004286
77. Chrencik, J. E.; Patny, A.; Leung, I. K.; Korniski, B.; Emmons, T. L.; Hall, T.; Weinberg, R. A.; Gormley, J. A.; Williams, J. M.; Day, J. E.; Hirsch, J. L.; Kiefer, J. R.; Leone, J. W.; Fischer, H. D.; Sommers, C. D.; Huang, H.-C.; Jacobsen, E. J.; Tenbrink, R. E.; Tomasselli, A. G.; Benson, T. E. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 2010, 400 (3), 413-433, 10.1016/j.jmb.2010.05.020
78. Lanier, M.; Pickens, J.; Bigi, S. V.; Bradshaw-Pierce, E. L.; Chambers, A.; Cheruvallath, Z. S.; Cole, D.; Dougan, D. R.; Ermolieff, J.; Gibson, T.; Halkowycz, P.; Hirokawa, A.; Ivetac, A.; Miura, J.; Nunez, E.; Sabat, M.; Tyhonas, J.; Wang, H.; Wang, X.; Swann, S. Structure-based design of ASK1 inhibitors as potential agents for heart failure. ACS Med. Chem. Lett. 2017, 8 (3), 316-320, 10.1021/acsmedchemlett.6b00481
79. Pennington, L. D.; Moustakas, D. T. The Necessary nitrogen atom: A versatile high-impact design element for multiparameter optimization. J. Med. Chem. 2017, 60 (9), 3552-3579, 10.1021/acs.jmedchem.6b01807
80. Bryan, M. C.; Falsey, J. R.; Frohn, M.; Reichelt, A.; Yao, G.; Bartberger, M. D.; Bailis, J. M.; Zalameda, L.; Miguel, T. S.; Doherty, E. M.; Allen, J. G. N-substituted azaindoles as potent inhibitors of Cdc7 kinase. Bioorg. Med. Chem. Lett. 2013, 23 (7), 2056-2060, 10.1016/j.bmcl.2013.02.007
81. Vanotti, E.; Amici, R.; Bargiotti, A.; Berthelsen, J.; Bosotti, R.; Ciavolella, A.; Cirla, A.; Cristiani, C.; D'Alessio, R.; Forte, B.; Isacchi, A.; Martina, K.; Menichincheri, M.; Molinari, A.; Montagnoli, A.; Orsini, P.; Pillan, A.; Roletto, F.; Scolaro, A.; Tibolla, M.; Valsasina, B.; Varasi, M.; Volpi, D.; Santocanale, C. Cdc7 kinase inhibitors: Pyrrolopyridinones as potential antitumor agents. 1. synthesis and structure-activity relationships. J. Med. Chem. 2008, 51 (3), 487-501, 10.1021/jm700956r
82. Chang, C. E.; Chen, W.; Gilson, M. K. Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (5), 1534-1539, 10.1073/pnas.0610494104
83. Breslin, H. J.; Lane, B. M.; Ott, G. R.; Ghose, A. K.; Angeles, T. S.; Albom, M. S.; Cheng, M.; Wan, W.; Haltiwanger, R. C.; Wells-Knecht, K. J.; Dorsey, B. D. Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-Tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles. J. Med. Chem. 2012, 55 (1), 449-464, 10.1021/jm201333e
84. Li, Z.; Partridge, J.; Silva-Garcia, A.; Rademacher, P.; Betz, A.; Xu, Q.; Sham, H.; Hu, Y.; Shan, Y.; Liu, B.; Zhang, Y.; Shi, H.; Xu, Q.; Ma, X.; Zhang, L. Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors. ACS Med. Chem. Lett. 2017, 8 (2), 185-190, 10.1021/acsmedchemlett.6b00384
85. Linton, M. A.; Burke, B. J.; Johnson, T. W.; Ninkovic, S.; Gajiwala, K. S.; Richardson, P.; Le, P. T. Effect of water solvation on the lipophilicity of isomeric pyrimidine-carboxamides. Bioorg. Med. Chem. 2015, 23 (13), 3408-3413, 10.1016/j.bmc.2015.04.041